Targeting the IGF1R Pathway in Breast Cancer Using Antisense lncRNA-Mediated Promoter cis Competition

Aberrant insulin-like growth factor I receptor (IGF1R) signaling pathway serves as a well-established target for cancer drug therapy. The intragenic antisense long noncoding RNA (lncRNA) IRAIN, a putative tumor suppressor, is downregulated in breast cancer cells, while IGF1R is overexpressed, leadin...

Descripción completa

Detalles Bibliográficos
Autores principales: Pian, Lingling, Wen, Xue, Kang, Lihua, Li, Zhaozhi, Nie, Yuanyuan, Du, Zhonghua, Yu, Dehai, Zhou, Lei, Jia, Lin, Chen, Naifei, Li, Dan, Zhang, Songling, Li, Wei, Hoffman, Andrew R., Sun, Jingnan, Cui, Jiuwei, Hu, Ji-Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023958/
https://www.ncbi.nlm.nih.gov/pubmed/30195750
http://dx.doi.org/10.1016/j.omtn.2018.04.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023958/
https://www.ncbi.nlm.nih.gov/pubmed/30195750
http://dx.doi.org/10.1016/j.omtn.2018.04.013

Ejemplares similares